MX2023004539A - Compuestos y metodos para el tratamiento de trastornos oculares. - Google Patents
Compuestos y metodos para el tratamiento de trastornos oculares.Info
- Publication number
- MX2023004539A MX2023004539A MX2023004539A MX2023004539A MX2023004539A MX 2023004539 A MX2023004539 A MX 2023004539A MX 2023004539 A MX2023004539 A MX 2023004539A MX 2023004539 A MX2023004539 A MX 2023004539A MX 2023004539 A MX2023004539 A MX 2023004539A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- treatment
- inflammatory
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000022873 Ocular disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001530 keratinolytic effect Effects 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 229940124091 Keratolytic Drugs 0.000 abstract 1
- 206010065062 Meibomian gland dysfunction Diseases 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 208000010217 blepharitis Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000000744 eyelid Anatomy 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/02—Five-membered rings
- C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
En el presente documento se describen composiciones y métodos para el tratamiento o la prevención de trastornos de la superficie ocular que incluyen disfunción de las glándulas de Meibomio, blefaritis, enfermedad del ojo seco y otras enfermedades inflamatorias y/o infecciosas de la superficie anterior del ojo u ojos. Dichas composiciones y métodos comprenden conjugados queratolíticos que demuestran actividad queratolítica y actividades antiinflamatorias u otras deseables. La administración tópica de dichas composiciones en el margen del párpado o áreas circundantes proporciona un beneficio terapéutico a los pacientes que padecen trastornos de la superficie ocular.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063094791P | 2020-10-21 | 2020-10-21 | |
| PCT/IB2021/000723 WO2022084747A1 (en) | 2020-10-21 | 2021-10-20 | Compounds and methods for the treatment of ocular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004539A true MX2023004539A (es) | 2023-06-15 |
Family
ID=81290149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004539A MX2023004539A (es) | 2020-10-21 | 2021-10-20 | Compuestos y metodos para el tratamiento de trastornos oculares. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4232458A1 (es) |
| JP (1) | JP2023546915A (es) |
| KR (1) | KR20230110514A (es) |
| CN (1) | CN116670116A (es) |
| AU (1) | AU2021363705A1 (es) |
| CA (1) | CA3196180A1 (es) |
| IL (1) | IL302175A (es) |
| MX (1) | MX2023004539A (es) |
| WO (1) | WO2022084747A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9828074D0 (en) * | 1998-12-18 | 1999-02-17 | Glaxo Group Ltd | Therapeutically useful compounds |
| GB0127423D0 (en) * | 2001-11-15 | 2002-01-09 | Glaxo Group Ltd | Process |
| JP5487214B2 (ja) * | 2008-12-19 | 2014-05-07 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物 |
| KR20220003555A (ko) * | 2019-04-18 | 2022-01-10 | 아주라 오프탈믹스 엘티디 | 안구 장애의 치료를 위한 화합물 및 방법 |
-
2021
- 2021-10-20 CN CN202180086912.3A patent/CN116670116A/zh active Pending
- 2021-10-20 EP EP21882233.6A patent/EP4232458A1/en active Pending
- 2021-10-20 KR KR1020237016454A patent/KR20230110514A/ko unknown
- 2021-10-20 IL IL302175A patent/IL302175A/en unknown
- 2021-10-20 MX MX2023004539A patent/MX2023004539A/es unknown
- 2021-10-20 CA CA3196180A patent/CA3196180A1/en active Pending
- 2021-10-20 AU AU2021363705A patent/AU2021363705A1/en active Pending
- 2021-10-20 WO PCT/IB2021/000723 patent/WO2022084747A1/en active Application Filing
- 2021-10-20 JP JP2023524275A patent/JP2023546915A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021363705A1 (en) | 2023-06-15 |
| CA3196180A1 (en) | 2022-04-28 |
| IL302175A (en) | 2023-06-01 |
| EP4232458A1 (en) | 2023-08-30 |
| KR20230110514A (ko) | 2023-07-24 |
| WO2022084747A1 (en) | 2022-04-28 |
| CN116670116A (zh) | 2023-08-29 |
| JP2023546915A (ja) | 2023-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020212760A3 (en) | Compounds and methods for the treatment of ocular disorders | |
| MX2023004537A (es) | Compuestos y metodos para el tratamiento de trastornos oculares. | |
| Ayyala et al. | Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes | |
| US8906427B2 (en) | Treatment for meibomian gland dysfunction or obstruction | |
| BRPI0608152A2 (pt) | formulações para tratamento ocular | |
| Yue et al. | Neuroprotective effect of curcumin against oxidative damage in BV-2 microglia and high intraocular pressure animal model | |
| JP2019534867A5 (es) | ||
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| JP7378781B2 (ja) | 脳神経の薬理学的な経皮活性化による神経変性障害に関連する症状の治療 | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| WO2015138628A8 (en) | Use of aav-expressed m013 protein as an anti-inflammatory therapeutic | |
| ECSP22086300A (es) | Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas | |
| MX2020006309A (es) | Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis. | |
| Deng et al. | Danhong enhances recovery from residual dizziness after successful repositioning treatment in patients with benign paroxysmal positional vertigo | |
| MX2022013665A (es) | Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares. | |
| KR102256185B1 (ko) | 멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법 | |
| CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
| MX2023004538A (es) | Compuestos y metodos para el tratamiento de trastornos oculares. | |
| MX2023004539A (es) | Compuestos y metodos para el tratamiento de trastornos oculares. | |
| AU2022370385A1 (en) | Compounds and methods for the treatment of dermal and ocular disorders | |
| AU2020299145A8 (en) | Compositions and methods for treating eye diseases | |
| JP2022530471A (ja) | 神経保護のためのカンナビノイドの組成物及び使用方法 | |
| MX2021009384A (es) | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. | |
| MX2021016055A (es) | Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis. |